Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 59,307 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 59,307 shares of Werewolf Therapeutics stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $0.69, for a total value of $40,921.83. Following the completion of the transaction, the director directly owned 2,782,650 shares in the company, valued at $1,920,028.50. This trade represents a 2.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Luke Evnin also recently made the following trade(s):

• On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total value of $66,249.66.
• On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $22,448.16.
• On Wednesday, December 24th, Luke Evnin sold 16,310 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.65, for a total transaction of $10,601.50.
• On Tuesday, December 23rd, Luke Evnin sold 71,428 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $44,999.64.
• On Wednesday, December 17th, Luke Evnin sold 9,983 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total transaction of $11,380.62.
• On Tuesday, December 16th, Luke Evnin sold 14,548 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.05, for a total transaction of $15,275.40.
• On Monday, December 15th, Luke Evnin sold 23,640 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.07, for a total transaction of $25,294.80.
• On Friday, December 12th, Luke Evnin sold 17,858 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.08, for a total value of $19,286.64.
• On Thursday, December 11th, Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.07, for a total value of $29,969.63.
• On Wednesday, December 10th, Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.06, for a total value of $39,330.24.

Werewolf Therapeutics Price Performance

Shares of HOWL stock opened at $0.62 on Tuesday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.56 and a fifty-two week high of $2.38. The firm has a market cap of $30.15 million, a P/E ratio of -0.38 and a beta of 0.74. The business’s 50 day moving average price is $1.06 and its 200-day moving average price is $1.29.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. On average, equities research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on HOWL. Citigroup lowered shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, December 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Wedbush downgraded Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 target price on the stock. in a report on Friday, December 19th. Bank of America decreased their target price on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Finally, Citizens Jmp cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, December 19th. Three analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $3.75.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in HOWL. Quadrature Capital Ltd bought a new stake in Werewolf Therapeutics in the second quarter worth $28,000. Qube Research & Technologies Ltd bought a new stake in Werewolf Therapeutics during the 2nd quarter valued at about $48,000. Nuveen LLC bought a new stake in Werewolf Therapeutics during the 1st quarter valued at about $71,000. AQR Capital Management LLC purchased a new position in Werewolf Therapeutics in the first quarter worth about $79,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Werewolf Therapeutics during the second quarter valued at approximately $92,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.